BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Tokyo:4593) 5/26/15 $59.6 $391.0 $416.5 7% Collegium Pharmaceutical Inc. (NASDAQ:COLL) 5/7/15 $80.0 $246.9 $367.1 49% Verseon Corp....
BioCentury | May 25, 2015
Finance

London calling

...European companies have been flocking to NASDAQ to raise cash from U.S. investors. But California's Verseon Corp....
...shares at 202p in an IPO on the London Stock Exchange's AIM. The price valued Verseon...
...$165 million) in 2014. Verseon has gained 9.5p to 211.5p since it started trading. Following Verseon's...
BioCentury | May 11, 2015
Financial News

Verseon completes IPO

Verseon Corp. (LSE:VSN), Fremont, Calif. Business: Cardiovascular, Cancer, Ophthalmic Date completed: 2015-05-07 Type: IPO Raised: L65.8 million ($99.6 million) Shares: 32.6 million Price: 202p Shares after offering: 149.7 million WIR Staff...
BioCentury | May 8, 2015
Financial News

Verseon raises L65.8M in IPO

...price values Verseon at L302.5 million ($457.9 million). Cenkos Securities plc was advisor and broker. Verseon...
...development. Verseon is developing direct thrombin inhibitors as oral anticoagulants for cardiovascular conditions. In 2009, Verseon...
...Kita held a combined 72.4% stake in the company. Additional investors included Godrej Industries and Verseon's...
Items per page:
1 - 4 of 4
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Tokyo:4593) 5/26/15 $59.6 $391.0 $416.5 7% Collegium Pharmaceutical Inc. (NASDAQ:COLL) 5/7/15 $80.0 $246.9 $367.1 49% Verseon Corp....
BioCentury | May 25, 2015
Finance

London calling

...European companies have been flocking to NASDAQ to raise cash from U.S. investors. But California's Verseon Corp....
...shares at 202p in an IPO on the London Stock Exchange's AIM. The price valued Verseon...
...$165 million) in 2014. Verseon has gained 9.5p to 211.5p since it started trading. Following Verseon's...
BioCentury | May 11, 2015
Financial News

Verseon completes IPO

Verseon Corp. (LSE:VSN), Fremont, Calif. Business: Cardiovascular, Cancer, Ophthalmic Date completed: 2015-05-07 Type: IPO Raised: L65.8 million ($99.6 million) Shares: 32.6 million Price: 202p Shares after offering: 149.7 million WIR Staff...
BioCentury | May 8, 2015
Financial News

Verseon raises L65.8M in IPO

...price values Verseon at L302.5 million ($457.9 million). Cenkos Securities plc was advisor and broker. Verseon...
...development. Verseon is developing direct thrombin inhibitors as oral anticoagulants for cardiovascular conditions. In 2009, Verseon...
...Kita held a combined 72.4% stake in the company. Additional investors included Godrej Industries and Verseon's...
Items per page:
1 - 4 of 4